A Prospective Study Of The LMB Regimen For Diffuse Large Cell Non Hodgkin's Lymphoma In Adults

References

• Fischer R. I., Gaynor E. R., Dahlberg S. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-hodgkin's lymphoma. New England Journal of Medicine 1993; 328: 1002–6
   PubMed Web of Science ®Google Scholar
• Miller T P, Dahlberg S, Cassady J R, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998; 339: 21–6
   PubMed Web of Science ®Google Scholar
• Wolf M, Matthews J P, Stone J, Cooper I A, Robertson T I, Fox R M. Long-term survival advantage of MACOP-B over CHOP in intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group. Ann Oncol 1997; 8(Suppl 1)71–-75
   PubMedGoogle Scholar
• Coiffier B. Fourteen years of high-dose CHOP (ACVB regimen): preliminary conclusions about the treatment of aggressive-lymphoma patients. Ann Oncol 1995; 6: 211–7
   PubMed Web of Science ®Google Scholar
• Shipp M A, Neuberg D, Janicek M, Canellos G P, Shulman L N. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study. J Clin Oncol 1995; 13: 2916–23
   PubMed Web of Science ®Google Scholar
• Haioun C., Lepage E, Gisselbrecht C., et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87–2. Groupe d'Etude des Lymphomes de I'Adulte. J Clin Oncol 1997; 15: 1131–7
   PubMed Web of Science ®Google Scholar
• Gianni A M, Bregni M, Siena S, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997; 336: 1290–7
   PubMed Web of Science ®Google Scholar
• Verdonck L F, van Putten W L, Hagenbeek A, et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 1995; 332: 1045–51
   PubMed Web of Science ®Google Scholar
• Reyes F, Lepage E, Morel P, et al. Failure of first line inductive high dose chemotherapy in poor risk patients with agressive lymphoma: updated results of the randomized LNH93–3 study. Blood 1997; 90: 594a, (abstract 2640)
   Web of Science ®Google Scholar
• Pane C., Philip T., Rodary C., et al. High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvment with a short intensive polychemo-therapy: results from the French Pediatric Oncology Society of a randomised trial of 216 children. J. Clin. Oncol. 1991; 9: 123–132
   PubMed Web of Science ®Google Scholar
• Patte C., Michon J., Bouffet E., et al. High survival rates of childhood B-cell lymphoma and leukemia as results of the LMB89 protocol. Proc Am Assoc. Clin. Oncol. 1992; 11: 340, on behalf of the SFOP: (abstract 1164)
   Google Scholar
• Patte C., Michon J., Behrendt C., et al. B cell large cell lymphoma of children: description and outcome when treated with the same regimen as Burkitt. Ann. Oncol 1992; 7(suppl. 3), on behalf of the SFOP; 29 (abstract 092)
   Google Scholar
• Philip T., Meckenstock R., Deconnick E., et al. Treatment of poor prognosis Burkitt's lymphoma in adults with the Societe Francaise d'Oncologie Pediatrique LMB protocol. A study of the Federation Nationale des Centres de Lutte contre le Cancer. Eur. J. Cancer 1992; 28A: 1954–1959
   PubMed Web of Science ®Google Scholar
• Soussain C., Patte C, Ostronoff M., et al. Small non-cleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols. Blood 1995; 86: 664–674
   Google Scholar
• Blay JY, Bouhour D., Carrie C., et al. The C5R protocol: a regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-Hodgkin's lymphoma of patients with no known cause of immunosuppression. Blood 1995; 86: 2922–2929
   PubMed Web of Science ®Google Scholar
• Kaplan E L, Meyer P. Non parametric estimation from incomplete observations. J.Am. Stat. Assoc. 1958; 53: 457–81
   Web of Science ®Google Scholar
• Shipp M. A., Harrington D. P., Anderson JR. for the International Non-Hodgkin's Lymphoma Prognostic Factors Project, et al. A predictive model for aggressive NHL. N. Engl. J. Med 1993; 329: 987–994
   Google Scholar
• Philip T, Guglielmi C., Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 1995: 1540–5, 333:
   Web of Science ®Google Scholar
• Miller T P, Dana B W, Weick J K, et al. Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas. Semin Hematol 1988; 25(Suppl 2)17–22
   PubMed Web of Science ®Google Scholar
• Jy Blay, Louis D., Bouffet E., et al. Management of Pediatric non Hodgkin's lymphoma. Blood Reviews 1991; 5: 90–97
   PubMed Web of Science ®Google Scholar
• Shipp M A, Yeap B Y, Harrington DP, et al. The m-BACOD combination chemotherapy regimen in large-cell lymphoma: analysis of the complete trial and comparison with the M-BACOD regimen. J. Clin. Oncol. 1990; 8: 84–93
   PubMed Web of Science ®Google Scholar
• Longo D L, DeVita V T. Superiority of ProMACE-CytaBOM in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomised trial. Journal of Clinical Oncology 1991; 9: 25–38, Jr, Duffey PL et al.:
   PubMed Web of Science ®Google Scholar